|
| 齐拉西酮对难治性抑郁症的增效作用研究 |
| Study of the Synergy of Ziprasidone in the Treatment of Refractory Depression |
| 投稿时间：2011-06-22 修订日期：2011-08-24 |
| DOI： |
| 中文关键词: 齐拉西酮 难治性抑郁症 增效剂 |
| 英文关键词:Ziprasidone Refractory depression Synergist |
| 基金项目: |
|
| 摘要点击次数: 1732 |
| 全文下载次数: 2853 |
| 中文摘要: |
| 摘 要 目的：观察齐拉西酮对难治性抑郁症的增效作用及其安全性。方法：67例难治性抑郁症患者随机分为观察组（文拉法辛联合齐拉西酮）32例，对照组（单用文拉法辛）35例。疗程8周，于治疗前及治疗后1、2、4、8周分别用汉密尔抑郁量表（HAMD）及临床总体印象量表（CGI）评定疗效，不良反应量表（TESS）评定不良反应及安全性。结果：两组治疗后HAMD、CGI评分均较治疗前显著下降（P<0.05或0.01），而合用组起效时间迅速，两组不良反应相仿。结论：增效剂治疗难治性抑郁症安全有效。 |
| 英文摘要: |
| ABSTRACT Objective:To observe the synergy and safety of ziprasidone in the treatment of refractory depression. Method:67 refractory depression patients were randomly divided into the combined group (venlafaxin combined with ziprasidone) and the controlled group (venlafaxin only) for their treatment for 8 weeks. The efficacy and adverse drug reaction were evaluated with HAMD, CGI and TESS at the end of the 1st, 2nd, 4th and 8th weeks. Result:The scores of HAMD and CGI were significantly reduced after every treatment time in the two groups (P<0.05 or0.01), but the work time of the combined group was quicker than that of the controlled group.Conclusion:Ziprasidone is safe and effective in treating refractory depression patients as the synergist. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
